CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
AU2002227052A1
(en)
|
2000-11-30 |
2002-06-11 |
University Of Florida |
Treatments for neurogenetic disorders, impulse control disorders, and wound healing
|
EP1953162B9
(fr)
*
|
2001-02-24 |
2012-10-31 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Dérivé de xanthine, sa fabrication et son utilisation en tant que médicament
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
ATE423559T1
(de)
*
|
2001-04-04 |
2009-03-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
|
JP2004536047A
(ja)
*
|
2001-04-11 |
2004-12-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法
|
EP1432720A1
(fr)
*
|
2001-09-05 |
2004-06-30 |
Bristol-Myers Squibb Company |
Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004031203A1
(fr)
|
2002-10-04 |
2004-04-15 |
Kissei Pharmaceutical Co., Ltd. |
Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
CN101260130A
(zh)
*
|
2003-01-03 |
2008-09-10 |
布里斯托尔-迈尔斯斯奎布公司 |
制备c-芳基葡糖苷sglt2抑制剂的方法
|
EP1457206A1
(fr)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
|
PL1980560T3
(pl)
|
2003-03-14 |
2011-11-30 |
Astellas Pharma Inc |
Pochodne C-glikozydowe do leczenia cukrzycy
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
US8785403B2
(en)
*
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
CA2549025A1
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Indole-o-glucosides substitues
|
AR045173A1
(es)
|
2003-08-01 |
2005-10-19 |
Tanabe Seiyaku Co |
Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
|
WO2005012242A2
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica Nv |
Benzimidazole-, benztriazole- et benzimidazolone-o-glucosides substitues
|
WO2005011592A2
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Indazoles-o-glucosides substitues
|
AR048376A1
(es)
*
|
2003-08-01 |
2006-04-26 |
Janssen Pharmaceutica Nv |
C- glicosidos heterociclos fusionados sustituidos
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
NZ549219A
(en)
*
|
2004-03-04 |
2010-08-27 |
Kissei Pharmaceutical |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
CN103435581B
(zh)
|
2004-03-16 |
2015-08-19 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
EP1750862B1
(fr)
|
2004-06-04 |
2011-01-05 |
Teva Pharmaceutical Industries Ltd. |
Composition pharmaceutique contenant de l'irbesartan
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
CA2574451A1
(fr)
*
|
2004-07-27 |
2006-02-02 |
Boehringer Ingelheim International Gmbh |
Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US20080139484A1
(en)
*
|
2004-09-29 |
2008-06-12 |
Kissei Pharmaceutical Co., Ltd. |
1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CA2582464A1
(fr)
*
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Modulation antisens de l'expression de ptp1b
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
ES2314743T3
(es)
*
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
TWI365186B
(en)
*
|
2005-01-31 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
ES2319461T3
(es)
*
|
2005-02-10 |
2009-05-07 |
Bristol-Myers Squibb Company |
Dihidroquinazolinonas como moduladores de 5ht.
|
WO2006089872A1
(fr)
*
|
2005-02-23 |
2006-08-31 |
Boehringer Ingelheim International Gmbh |
Derives d'(hetero)arylethynyl-benzyd-benzene a substitution glucopyranosyle et leur utilisation en tant que cotransporteur 2 de glucose dependant de sodium (sglt2)
|
EP1874787B1
(fr)
*
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(fr)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
WO2007014894A2
(fr)
*
|
2005-07-27 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire
|
CA2617102A1
(fr)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EP1924571B1
(fr)
*
|
2005-08-30 |
2010-10-13 |
Boehringer Ingelheim International Gmbh |
Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
|
RU2008113050A
(ru)
*
|
2005-09-08 |
2009-10-20 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
GEP20105033B
(en)
*
|
2005-12-28 |
2010-06-25 |
Takeda Pharmaceuticals Co |
Therapeutic agent for diabetes
|
TW200801029A
(en)
|
2006-02-15 |
2008-01-01 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
US20090176717A1
(en)
*
|
2006-06-01 |
2009-07-09 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
AU2007293673B2
(en)
*
|
2006-09-07 |
2013-06-27 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
EP2072522A4
(fr)
*
|
2006-10-13 |
2010-01-06 |
Chugai Pharmaceutical Co Ltd |
Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
|
US8283326B2
(en)
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
CN101611032B
(zh)
*
|
2006-12-04 |
2012-07-18 |
詹森药业有限公司 |
作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
CN101657471B
(zh)
|
2006-12-06 |
2013-07-03 |
史密丝克莱恩比彻姆公司 |
二环化合物及其作为抗糖尿病药的用途
|
US8198464B2
(en)
|
2006-12-21 |
2012-06-12 |
Astellas Pharma Inc. |
Method for producing C-glycoside derivative and intermediate for synthesis thereof
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
TW200904405A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
DK2183263T3
(da)
*
|
2007-07-26 |
2012-01-30 |
Lexicon Pharmaceuticals Inc |
Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
CL2008002425A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
|
EP3542801A1
(fr)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Dérivés de la purine destinés à être utilisés dans le traitement de maladies associées à fab
|
RU2497526C2
(ru)
*
|
2007-08-23 |
2013-11-10 |
Теракос, Инк. |
Производные бензилбензола и способы их применения
|
WO2009035969A1
(fr)
*
|
2007-09-10 |
2009-03-19 |
Janssen Pharmaceutica N.V. |
Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
US8648085B2
(en)
*
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
CN101969944B
(zh)
*
|
2008-01-31 |
2013-04-10 |
安斯泰来制药有限公司 |
脂肪性肝病的治疗用医药组合物
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
WO2009143010A1
(fr)
*
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Procédé de traitement d'une hyponatrémie à l'aide d'un inhibiteur de sglt2 et composition le contenant
|
CN102105153B
(zh)
*
|
2008-05-22 |
2014-03-05 |
百时美施贵宝公司 |
Sglt2抑制剂的医药用途和含该抑制剂的组合物
|
US8603989B2
(en)
*
|
2008-05-22 |
2013-12-10 |
Bristol-Myers Squibb Company |
Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
MX2011000637A
(es)
*
|
2008-07-15 |
2011-05-02 |
Theracos Inc |
Derivados deuretados de bencilbenceno y metodos de uso.
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
PE20110297A1
(es)
*
|
2008-08-15 |
2011-05-26 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 para la cicatrizacion de heridas
|
SG193168A1
(en)
*
|
2008-08-22 |
2013-09-30 |
Theracos Inc |
Processes for the preparation of sglt2 inhibitors
|
BRPI0918841B8
(pt)
*
|
2008-08-28 |
2021-05-25 |
Pfizer |
derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
|
AP2011005672A0
(en)
|
2008-09-08 |
2011-04-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of CNS disorders.
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
MX2011002989A
(es)
*
|
2008-09-19 |
2011-04-11 |
Novartis Ag |
Derivados de glicosido y usos de los mismos.
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
WO2010045656A2
(fr)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Nouvelles formes posologiques d'inhibiteur sglt2
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
WO2010092125A1
(fr)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
|
SG173587A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
CN102387783A
(zh)
|
2009-02-13 |
2012-03-21 |
贝林格尔.英格海姆国际有限公司 |
包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途
|
WO2010095768A1
(fr)
*
|
2009-02-23 |
2010-08-26 |
Taisho Pharmaceutical Co., Ltd. |
Composés de 4–isopropylphényl glucitol comme inhibiteurs de sglt1
|
EP2226076A1
(fr)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Support d'enregistrement thermosensible et procédé d'enregistrement
|
NZ594567A
(en)
|
2009-03-31 |
2013-12-20 |
Boehringer Ingelheim Int |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
CN106075451A
(zh)
*
|
2009-05-27 |
2016-11-09 |
阿斯利康(瑞典)有限公司 |
使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
EP2451797B1
(fr)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
Procédé de cristallisation pour le 1-(bêta -D-glucopyranosyl)-4-méthyl-3-[5-(4-fluorophényl)-2-thiènylméthyl] benzène
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
PT2486029E
(pt)
*
|
2009-09-30 |
2015-10-14 |
Boehringer Ingelheim Int |
Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
|
EP2483286B1
(fr)
*
|
2009-09-30 |
2016-07-13 |
Boehringer Ingelheim International GmbH |
Procédé de préparation d'une forme cristalline de 1-chloro-4-( -d-glucopyranos-1-yl)-2-[4-((s)-tétrahydrofuran-3-yloxy)-benzyl]-benzène
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
WO2011047113A1
(fr)
*
|
2009-10-14 |
2011-04-21 |
Janssen Pharmaceutica Nv |
Procédé de préparation de composés utiles comme inhibiteurs de sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
ME02016B
(me)
|
2009-11-02 |
2015-05-20 |
Pfizer |
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
|
RS57926B1
(sr)
|
2009-11-13 |
2019-01-31 |
Astrazeneca Ab |
Formulacije tablete sa trenutnim oslobađanjem
|
CA2780939C
(fr)
*
|
2009-11-13 |
2018-06-12 |
Bristol-Myers Squibb Company |
Formulations de comprime bicouche
|
WO2011058193A1
(fr)
|
2009-11-16 |
2011-05-19 |
Mellitech |
Dérivés de [1,5]-diazocine
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
WO2011070592A2
(fr)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Nouveaux dérivés de sucres
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
WO2011120923A1
(fr)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Composition pharmaceutique comprenant un inhibiteur sglt2 et un agoniste ppar-gamma, utilisations correspondantes
|
WO2011138421A1
(fr)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combinaison thérapeutique
|
CN108354930A
(zh)
|
2010-05-11 |
2018-08-03 |
詹森药业有限公司 |
包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
|
EP2568971B1
(fr)
|
2010-05-11 |
2020-10-14 |
Mitsubishi Tanabe Pharma Corporation |
Comprimés contenant de la canagliflozine
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
EP3366304B1
(fr)
|
2010-06-24 |
2020-05-13 |
Boehringer Ingelheim International GmbH |
Traitement du diabète
|
WO2012020022A1
(fr)
|
2010-08-12 |
2012-02-16 |
Boehringer Ingelheim International Gmbh |
Dérivés de 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leurs utilisations en tant qu'inhibiteurs de pde9a
|
WO2012025857A1
(fr)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
|
CN103370064A
(zh)
|
2010-09-03 |
2013-10-23 |
百时美施贵宝公司 |
使用水溶性抗氧化剂的药物制剂
|
US8921328B2
(en)
|
2010-09-14 |
2014-12-30 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(fr)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
MX2013008372A
(es)
|
2011-02-01 |
2013-08-12 |
Astrazeneca Uk Ltd |
Formulaciones farmaceuticas que incluyen compuesto de amina.
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
US8980829B2
(en)
|
2011-02-18 |
2015-03-17 |
Shanghai Yingli Science And Technology Co., Ltd |
Aryl glycoside compound, preparation method and use thereof
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
HUE030116T2
(en)
|
2011-04-13 |
2017-04-28 |
Janssen Pharmaceutica Nv |
A method for preparing compounds useful as inhibitors of SGLT2
|
WO2012146075A1
(fr)
*
|
2011-04-25 |
2012-11-01 |
北京普禄德医药科技有限公司 |
Inhibiteur des transporteurs sodium/glucose, son procédé de préparation et son utilisation
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
CN103649033B
(zh)
*
|
2011-05-26 |
2016-02-24 |
Tf化学公司 |
芳基、杂芳基、o-芳基和o-杂芳基碳环糖家族
|
CA2837232A1
(fr)
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Composition pharmaceutique comprenant de la dapagliflozine et de la cyclodextrine
|
BR112013031032A2
(pt)
|
2011-06-03 |
2016-11-29 |
Boehringer Ingelheim Int |
inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
|
ES2448398T3
(es)
|
2011-06-03 |
2014-03-13 |
Ratiopharm Gmbh |
Composición farmacéutica que comprende dapagliflozina y ciclodextrina
|
US9562029B2
(en)
|
2011-06-25 |
2017-02-07 |
Xuanzhu Pharma Co., Ltd. |
C-glycoside derivatives
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2013010964A1
(fr)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Quinazolines substituées, la préparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
|
EP2755722B1
(fr)
|
2011-09-13 |
2017-05-24 |
Panacea Biotec Ltd. |
Nouveaux inhibiteurs de sglt
|
KR20140097258A
(ko)
*
|
2011-10-31 |
2014-08-06 |
시노팜 타이완 리미티드 |
Sglt2 억제제의 결정성 및 비-결정성 형태
|
EP2597090A1
(fr)
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Hydrate de dapagliflozine cristalline
|
KR102055958B1
(ko)
|
2011-12-22 |
2019-12-13 |
글리코미메틱스, 인크. |
E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
CN103450214B
(zh)
*
|
2012-05-29 |
2016-04-06 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(fr)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
SG11201501510SA
(en)
*
|
2012-08-30 |
2015-04-29 |
Taisho Pharmaceutical Co Ltd |
Combinations of sglt2 inhibitors and antihypertensive drugs
|
US9867841B2
(en)
|
2012-12-07 |
2018-01-16 |
Glycomimetics, Inc. |
Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(fr)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
ES2740299T3
(es)
|
2013-03-14 |
2020-02-05 |
Msd Int Gmbh |
Métodos para preparar inhibidores de SGLT2
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
ES2959444T3
(es)
|
2013-04-04 |
2024-02-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
ES2702174T3
(es)
|
2013-04-05 |
2019-02-27 |
Boehringer Ingelheim Int |
Usos terapéuticos de empagliflozina
|
EA033286B1
(ru)
|
2013-04-18 |
2019-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения или отсрочки развития хронической болезни почек
|
EP2991999B1
(fr)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Co-cristal de dapagliflozine et de lactose
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015040571A1
(fr)
|
2013-09-23 |
2015-03-26 |
Ranbaxy Laboratories Limited |
Méthode de préparation de dapagliflozine
|
EP3049397A1
(fr)
*
|
2013-09-27 |
2016-08-03 |
Sun Pharmaceutical Industries Ltd |
Procédé de purification de dapagliflozin
|
EP2895490B1
(fr)
|
2013-09-27 |
2016-10-19 |
Sunshine Lake Pharma Co., Ltd. |
Dérivés de glucopyranosyl et leurs utilisations en médecine
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
WO2015063726A1
(fr)
|
2013-10-31 |
2015-05-07 |
Ranbaxy Laboratories Limited |
Procédé de préparation de 4-bromo-1-chloro-2-(4-éthoxybenzyl)benzène
|
EP4285995A3
(fr)
|
2013-12-17 |
2024-02-28 |
Boehringer Ingelheim Vetmedica GmbH |
Un inhibiteur de sglt-2 pour le traitement des troubles métaboliques chez les félins
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
CN104761522B
(zh)
*
|
2014-01-03 |
2017-02-15 |
山东轩竹医药科技有限公司 |
光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
KR20220097538A
(ko)
|
2014-01-23 |
2022-07-07 |
베링거잉겔하임베트메디카게엠베하 |
개과 동물에서 대사 장애의 치료
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(fr)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
WO2015128853A1
(fr)
|
2014-02-28 |
2015-09-03 |
Sun Pharmaceutical Industries Limited |
Compositions de dapagliflozin
|
EP3114115A4
(fr)
*
|
2014-03-06 |
2017-08-23 |
MSN Laboratories Private Limited |
Procédé pour la préparation de (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-éthoxyphényl)méthyl]phényl]-d-glucitol et de son solvate
|
NZ723781A
(en)
|
2014-04-01 |
2022-09-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP3142661B1
(fr)
*
|
2014-05-16 |
2021-10-06 |
Astrazeneca AB |
Méthode de suppression de la sécrétion de glucagon d'un inhibiteur de sglt2
|
EP2944311A1
(fr)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
|
EP3229814A4
(fr)
|
2014-06-23 |
2018-07-11 |
Sun Pharmaceutical Industries Ltd |
Co-cristal de dapagliflozin et d'acide citrique
|
RU2695652C2
(ru)
|
2014-09-25 |
2019-07-25 |
Астразенека Аб |
Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
JP6689854B2
(ja)
|
2014-12-03 |
2020-04-28 |
グリコミメティクス, インコーポレイテッド |
E−セレクチンおよびcxcr4ケモカイン受容体のヘテロ二官能性阻害剤
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
EP3256482B1
(fr)
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Procédé de préparation de composés inhibiteurs de sglt
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
WO2016161995A1
(fr)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Formes solides de dapagliflozine amorphe
|
WO2016178148A1
(fr)
*
|
2015-05-05 |
2016-11-10 |
Glenmark Pharmaceuticals Limited |
Procédé de préparation de dapagliflozine
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
US10428053B2
(en)
|
2015-09-15 |
2019-10-01 |
Laurus Labs Limited |
Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのsglt−2阻害剤
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
HUE051212T2
(hu)
*
|
2016-01-04 |
2021-03-01 |
Jeil Pharmaceutical Co Ltd |
Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
|
WO2017118945A1
(fr)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Prémélange de dapagliflozine et son procédé de préparation
|
CA3009836A1
(fr)
|
2016-01-22 |
2017-07-27 |
Glycomimetics, Inc. |
Inhibiteurs glycomimetiques des lectines pa-il et pa-iil
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
WO2017151708A1
(fr)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
|
JP2019512537A
(ja)
|
2016-03-31 |
2019-05-16 |
ルピン・リミテッド |
ダパグリフロジンの医薬組成物
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
EP3466939B1
(fr)
*
|
2016-05-24 |
2021-02-24 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Nouvelle forme cristalline de la dapagliflozine, son procédé de préparation et son utilisation
|
WO2017203229A1
(fr)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Prémélanges de dapagliflozine
|
EP3468562A1
(fr)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinaisons de linagliptine et de metformine
|
WO2018002673A1
(fr)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
|
EP3497131B1
(fr)
|
2016-08-08 |
2022-03-09 |
GlycoMimetics, Inc. |
Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
|
ES2926403T3
(es)
*
|
2016-08-09 |
2022-10-25 |
Laurus Labs Ltd |
Nuevos procedimientos para la preparación de dapagliflozina o sus solvatos o co-cristales de la misma
|
WO2018029264A1
(fr)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Procédé de préparation de dapagliflozine et de ses intermédiaires
|
KR102607640B1
(ko)
|
2016-10-07 |
2023-11-28 |
글리코미메틱스, 인크. |
매우 강력한 다량체성 e-셀렉틴 길항물질
|
JP2019531320A
(ja)
|
2016-10-19 |
2019-10-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(fr)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Procédé de préparation de dapagliflozine
|
US11197877B2
(en)
|
2017-03-15 |
2021-12-14 |
Glycomimetics. Inc. |
Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
|
WO2018167589A1
(fr)
|
2017-03-16 |
2018-09-20 |
Inventia Healthcare Private Limited |
Composition pharmaceutique comprenant de la dapagliflozine
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
WO2018207111A1
(fr)
*
|
2017-05-09 |
2018-11-15 |
Piramal Enterprises Limited |
Procédé de préparation d'inhibiteurs de sglt2 et de ses intermédiaires
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
EP3717013A1
(fr)
|
2017-11-30 |
2020-10-07 |
GlycoMimetics, Inc. |
Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
|
AU2018395417B2
(en)
|
2017-12-29 |
2023-07-13 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
CA3091454A1
(fr)
|
2018-03-05 |
2019-09-12 |
Glycomimetics, Inc. |
Methodes de traitement de la leucemie aigue myeloide et d'etats pathologiques associes
|
US20210113561A1
(en)
|
2018-04-17 |
2021-04-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(fr)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
Nouveau procédé de préparation d'inhibiteurs de sglt-2
|
KR20200005320A
(ko)
|
2018-07-06 |
2020-01-15 |
한미약품 주식회사 |
무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
|
CA3105626A1
(fr)
*
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
WO2020039394A1
(fr)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
Nouvelles combinaisons de médicaments
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
BR112020008705A2
(pt)
|
2019-08-30 |
2022-03-22 |
Astrazeneca Ab |
Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
|
US11759474B2
(en)
|
2019-11-28 |
2023-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
AU2021222297A1
(en)
|
2020-02-17 |
2022-08-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
WO2021165316A1
(fr)
|
2020-02-21 |
2021-08-26 |
Zakłady Farmaceutyczne POLPHARMA S.A. |
Composition pharmaceutique comprenant de la dapagliflozine
|
EP4114365A1
(fr)
|
2020-03-05 |
2023-01-11 |
KRKA, d.d., Novo mesto |
Composition pharmaceutique comprenant un inhibiteur du sglt2
|
KR20220151634A
(ko)
|
2020-03-06 |
2022-11-15 |
버텍스 파마슈티칼스 인코포레이티드 |
Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
|
JP2023523596A
(ja)
|
2020-04-22 |
2023-06-06 |
バイエル アクチェンゲゼルシャフト |
心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
WO2021245253A1
(fr)
|
2020-06-05 |
2021-12-09 |
Krka, D.D., Novo Mesto |
Préparation de dapagliflozine amorphe très pure
|
WO2021260617A1
(fr)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
|
CA3188345A1
(fr)
|
2020-07-10 |
2022-01-13 |
Astrazeneca Ab |
Combinaison de zibotentan et de dapagliflozine pour le traitement d'une maladie renale chronique
|
WO2022022865A1
(fr)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Procédés de traitement d'une maladie rénale chronique avec de la dapagliflozine
|
WO2022051316A1
(fr)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
|
EP4206212A4
(fr)
|
2020-09-30 |
2024-05-22 |
Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. |
Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
WO2022119543A1
(fr)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
WO2022208172A1
(fr)
|
2021-04-01 |
2022-10-06 |
Astrazeneca Uk Limited |
Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine
|
EP4079296A1
(fr)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
EP4376819A1
(fr)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
|
WO2023006718A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez des mammifères non humains à l'exclusion de félins, en particulier des canidés
|
CA3224673A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prevention et/ou le traitement de maladies renales chez des mammiferes non humains
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(fr)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Combinaison d'obicetrapib et d'inhibiteur de sglt2
|
EP4212150A1
(fr)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2023237512A1
(fr)
|
2022-06-07 |
2023-12-14 |
Astrazeneca Ab |
Combinaisons de modulateurs de rxfp1 et d'inhibiteurs de sglt2
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|